Anna Fioravanti

Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer

Andrea Fontana, Luca Galli, Anna Fioravanti et al. · Clinical Cancer Research · 2009 · 88 citations

Medicine, Pharmacology, Pharmacotherapy +17

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers

Giacomo Allegrini, Teresa Di Desidero, M. Barletta et al. · Angiogenesis · 2012 · 72 citations · Full text

Medicine, Oncology, Pharmacology +17

Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer

Alessandro Antonelli, Guido Bocci, Concettina La Motta et al. · The Journal of Clinical Endocrinology & Metabolism · 2010 · 67 citations

Medicine, Oncology, Pharmacology +13

CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo

Alessandro Antonelli, Guido Bocci, Concettina La Motta et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 57 citations · Full text

Medicine, Oncology, Pharmacology +9

CLM3, a Multitarget Tyrosine Kinase Inhibitor With Antiangiogenic Properties, Is Active Against Primary Anaplastic Thyroid Cancer In Vitro and In Vivo

Alessandro Antonelli, Guido Bocci, Poupak Fallahi et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 51 citations · Full text

Medicine, Oncology, Pharmacology +17